SWEDISH ORPHAN BIOVITRUM

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 2010-01-01

Employees: -

Market Cap: $10.7B

Website: http://www.sobi.com/

Clinical Trials

A Study to Assess the Safety and Tolerability of SOBI003 in Pediatric MPS IIIA Patients

Phase 1

Completed

Conditions: Sanfilippo Syndrome Type A (MPS IIIA)

Interventions: Drug: SOBI003

First Posted Date: 2018-02-06

Last Posted Date: 2021-11-19

Lead Sponsor: Swedish Orphan Biovitrum

Target Recruit Count: 6

Registration Number: NCT03423186

Locations: 🇺🇸
Childrens's Hospital and Research Center, Oakland, California, United States
🇺🇸
University of North Carolina Hospitals, Chapel Hill, North Carolina, United States
🇹🇷
Gazi University Hospital, Ankara, Turkey

and more 1 locations

Study to Assess the Efficacy and Safety of Emapalumab in Primary Haemophagocytic Lymphohistiocytosis

Phase 3

Completed

Conditions: Primary Hemophagocytic Lymphohistiocytosis

Interventions: Drug: Emapalumab

First Posted Date: 2017-10-18

Last Posted Date: 2024-03-12

Lead Sponsor: Swedish Orphan Biovitrum

Target Recruit Count: 35

Registration Number: NCT03312751

Locations: 🇺🇸
Texas Children's Hospital - Feigin Center, Houston, Texas, United States
🇺🇸
Cincinnati Children's Hospital, Cincinnati, Ohio, United States
🇺🇸
Seattle Children's Hospital, Seattle, Washington, United States

and more 24 locations

A Study to Investigate the Safety and Efficacy of Emapalumab, an Anti-IFN-gamma mAb in Patients With Systemic Juvenile Idiopathic Arthritis (sJIA) or Adult-onset Still's Disease (AOSD) Developing Macrophage Activation Syndrome/Secondary HLH (MAS/sHLH)

Phase 2

Completed

Conditions: Arthritis, Juvenile
Lymphohistiocytosis, Hemophagocytic
Adult Onset Still Disease
Macrophage Activation Syndrome

Interventions: Drug: Emapalumab

First Posted Date: 2017-10-17

Last Posted Date: 2022-05-17

Lead Sponsor: Swedish Orphan Biovitrum

Target Recruit Count: 14

Registration Number: NCT03311854

Locations: 🇮🇹
IRCCS Ospedale Pediatrico, Bambino Gesù, Rome, Italy
🇬🇧
Great Ormond Street Hospital for Children, London, United Kingdom
🇪🇸
Hospital Sant Joan de Deu, Barcelona, Spain

and more 2 locations

Management of Health-Related QoL Impairment, Including Pain, Depression and Anxiety, in People With Haemophilia A and B

Completed

Conditions: Haemophilia A
Haemophilia B

First Posted Date: 2017-09-08

Last Posted Date: 2024-03-06

Lead Sponsor: Swedish Orphan Biovitrum

Target Recruit Count: 2300

Registration Number: NCT03276130

Locations: 🇸🇪
Swedish Orphan Biovitrum Research Site, Stockholm, Sweden

A Study to Evaluate Efficacy and Safety of Anakinra in the Treatment of Still's Disease (SJIA and AOSD)

Phase 3

Terminated

Conditions: Still's Disease, Adult-Onset
Still's Disease, Juvenile-Onset

Interventions: Biological: anakinra
Drug: Placebo

First Posted Date: 2017-08-29

Last Posted Date: 2021-06-30

Lead Sponsor: Swedish Orphan Biovitrum

Target Recruit Count: 13

Registration Number: NCT03265132

Locations: 🇺🇸
MetroHealth System, Cleveland, Ohio, United States
🇺🇸
Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States
🇺🇸
University of Vermont Medical Center, Burlington, Vermont, United States

and more 36 locations

A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis

Phase 3

Recruiting

Conditions: Post-essential Thrombocythemia Myelofibrosis
Post-polycythemia Vera Myelofibrosis
Primary Myelofibrosis

Interventions: Drug: Pacritinib
Drug: Physician's Choice medications

First Posted Date: 2017-05-24

Last Posted Date: 2024-11-21

Lead Sponsor: Swedish Orphan Biovitrum

Target Recruit Count: 399

Registration Number: NCT03165734

Locations: 🇺🇸
The James Cancer Hospital and Solove Research Institute, Columbus, Ohio, United States
🇮🇳
Shri Ram Cancer Centre, Mahatma Gandhi Medical College & Hospital, Jaipur, Rajasthan, India
🇮🇳
Gauhati Medical College and Hospital, Guwahati, Assam, India

and more 178 locations

A Study to Investigate the Potential Influence of Nitisinone on the Metabolism and the Transport of Other Drugs in Healthy Volunteers

Phase 1

Completed

Conditions: Drug Drug Interaction

Interventions: Drug: Nitisinone in Arm A
Drug: Furosemide
Drug: Nitisinone in Arm B
Drug: Tolbutamide
Drug: Metoprolol
Drug: Chlorzoxazone

First Posted Date: 2017-04-06

Last Posted Date: 2017-08-10

Lead Sponsor: Swedish Orphan Biovitrum

Target Recruit Count: 36

Registration Number: NCT03103568

Locations: 🇩🇪
PAREXEL EPCU Berlin, Berlin, Germany

Study of rFVIIIFc for Immune Tolerance Induction (ITI) in Haemophilia A Patients With Inhibitors Who Have Failed Previous ITI Therapies

Phase 4

Completed

Conditions: Hemophilia A

Interventions: Biological: Recombinant coagulation factor (rFVIIIFc)

First Posted Date: 2017-04-06

Last Posted Date: 2022-03-18

Lead Sponsor: Swedish Orphan Biovitrum

Target Recruit Count: 16

Registration Number: NCT03103542

Locations: 🇬🇧
Swedish Orphan Biovitrum Research Site, London, United Kingdom
🇸🇪
Swedish Orphan Biovitrum Research site, Gothenburg, Sweden

A Study to Evaluate the Real-world Usage and Effectiveness of Elocta and Alprolix in Patients With Haemophilia A or B

Completed

Conditions: Haemophilia A
Haemophilia B

Interventions: Drug: ELOCTA
Drug: ALPROLIX

First Posted Date: 2017-02-16

Last Posted Date: 2024-10-02

Lead Sponsor: Swedish Orphan Biovitrum

Target Recruit Count: 201

Registration Number: NCT03055611

Locations: 🇩🇪
Swedish Orphan Biovitrum Reserach site, Münster, Germany
🇩🇪
Swedish Orphan Biovitrum Reserach Site, Mörfelden-Walldorf, Germany
🇩🇪
Swedish Orphan Biovitrum Research Site, Würzburg, Germany

A Study to Evaluate Efficacy and Safety of Anakinra in the Treatment of Acute Gouty Arthritis

Phase 2

Completed

Conditions: Acute Gouty Arthritis

Interventions: Drug: Anakinra 100 mg
Drug: Triamcinolone Acetonide 40 mg
Drug: Placebo to Anakinra 100 mg
Drug: Placebo to Triamcinolone Acetonide 40 mg

First Posted Date: 2016-12-26

Last Posted Date: 2020-07-15

Lead Sponsor: Swedish Orphan Biovitrum

Target Recruit Count: 165

Registration Number: NCT03002974

Locations: 🇺🇸
Clinical Trials Management, Metairie, Louisiana, United States
🇺🇸
Clinical Research Solutions - Franklin, Franklin, Tennessee, United States
🇺🇸
Advanced Research Center, Anaheim, California, United States

and more 34 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy